prime DX TEST

Cancer molecular test

prime DX is a molecular test of 1021 oncogenes associated with targeted therapies and also includes three important biomarkers (PD-L1, MSI and TMB) associated with response to immunotherapy and LOH biomarker, for response to PARP therapy inhibitors. Information from the prime DX test can help the doctor in the prognosis of the patient’s cancer and in predicting the patient’s response to treatment, including immunotherapy, chemotherapy and PARP inhibitors.

It requires a paraffin block with the tumor tissue or plasma for the prime DX Liquid and takes about 15 working days for results.

To see a sample of the Results Report click on the link

RESULTS REPORT